Back to Search
Start Over
Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial.
- Source :
-
Circulation [Circulation] 2019 Mar 05; Vol. 139 (10), pp. 1341-1343. - Publication Year :
- 2019
- Subjects :
- Atherosclerosis blood
Atherosclerosis epidemiology
Biomarkers blood
Clinical Decision-Making
Clinical Trials as Topic
Dyslipidemias blood
Dyslipidemias epidemiology
Eicosapentaenoic Acid adverse effects
Eicosapentaenoic Acid economics
Eicosapentaenoic Acid therapeutic use
Humans
Hypolipidemic Agents adverse effects
Lipids blood
Multicenter Studies as Topic
Patient Selection
Risk Factors
Treatment Outcome
United States epidemiology
United States Department of Veterans Affairs
Veterans Health Services
Atherosclerosis economics
Atherosclerosis prevention & control
Drug Costs
Dyslipidemias drug therapy
Dyslipidemias economics
Eicosapentaenoic Acid analogs & derivatives
Eligibility Determination economics
Hypolipidemic Agents economics
Hypolipidemic Agents therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1524-4539
- Volume :
- 139
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Circulation
- Publication Type :
- Report
- Accession number :
- 30865483
- Full Text :
- https://doi.org/10.1161/CIRCULATIONAHA.118.038691